InHealth launches relocatable radioligand therapy service

InHealth is launching what it says is the UK’s first relocatable radioligand therapy (RLT) service, an innovative approach to cancer treatment.

While RLT, also known as molecular radiotherapy, is already available in the UK at a small number of static locations, InHealth expects it to play a much more integral role in cancer treatment in the near future. The therapy uses radiation to target cancer cells using specific molecules or ligands, and typically supports patients with neuroendocrine tumours and prostate cancer. InHealth’s existing PETCT service already supports more than 20,000 UK cancer patients each year through mobile and static sites. “What makes this new RLT service unique and exciting is that we will be offering it through the world’s first relocatable facility,” the company says.

“Not only will this service provide additional capacity to existing sites that offer the care from acute hospitals and static locations, but since it can be moved and relocated on a daily basis, InHealth will be able to support patients in new and harder to reach locations, providing a service that has never been an option because of geographical constraints.”

Picture: The RLT service will support existing sites and harder to reach locations.

Published on page 4 of the March 2024 issue of RAD Magazine.